Cargando…
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162691/ https://www.ncbi.nlm.nih.gov/pubmed/30201941 http://dx.doi.org/10.3390/cancers10090322 |
_version_ | 1783359197769891840 |
---|---|
author | Yamazaki, Hideya Masui, Koji Suzuki, Gen Nakamura, Satoaki Shimizu, Daisuke Nishikawa, Tatsuyuki Okabe, Haruumi Yoshida, Ken Kotsuma, Tadayuki Tanaka, Eiichi Otani, Keisuke Yoshioka, Yasuo Ogawa, Kazuhiko |
author_facet | Yamazaki, Hideya Masui, Koji Suzuki, Gen Nakamura, Satoaki Shimizu, Daisuke Nishikawa, Tatsuyuki Okabe, Haruumi Yoshida, Ken Kotsuma, Tadayuki Tanaka, Eiichi Otani, Keisuke Yoshioka, Yasuo Ogawa, Kazuhiko |
author_sort | Yamazaki, Hideya |
collection | PubMed |
description | The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability treatment weighting (IPTW) with propensity scores. The actuarial five-year biochemical failure-free survival rates were 92.9% and 96.7% (p = 0.1847; p = 0.077 in IPTW) for HDR-BT and IG-IMRT, respectively; they were 100% and 95.8% (p = 0.286) for the low-risk group, 95.6% and 92% (p = 0.42) for the intermediate-risk group, 90.4% and 84.9% (p = 0.1059; p = 0.04 in IPTW) for the high-risk group, and 87.1% and 89.2% (p = 0.3816) for the very-high-risk group. In the assessment of accumulated incidences of grade ≥ 2 toxicity (Common Terminology Criteria for Adverse Events version 4.0) at five years, HDR-BT monotherapy showed higher genitourinary toxicity (11.9%) than IG-IMRT (3.3%) (p < 0.0001). The gastrointestinal toxicity was equivalent for HDR-BT (2.3%) and IG-IMRT (5.5%) (p = 0.063). No Grade 4 or 5 toxicity was detected in either modality. HDR-BT showed higher genitourinary toxicity than IG-IMRT. HDR-BT and IG-IMRT showed equivalent outcomes in low-, intermediate-, and very-high-risk groups. For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT. |
format | Online Article Text |
id | pubmed-6162691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61626912018-10-02 High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer Yamazaki, Hideya Masui, Koji Suzuki, Gen Nakamura, Satoaki Shimizu, Daisuke Nishikawa, Tatsuyuki Okabe, Haruumi Yoshida, Ken Kotsuma, Tadayuki Tanaka, Eiichi Otani, Keisuke Yoshioka, Yasuo Ogawa, Kazuhiko Cancers (Basel) Article The aim of this paper is to compare outcomes between high-dose-rate interstitial brachytherapy (HDR-BT) monotherapy and image-guided intensity-modulated radiotherapy (IG-IMRT) for localized prostate cancer. We examined 353 HDR-BT and 270 IG-IMRT patients. To reduce background selection bias, we used the method of inverse probability treatment weighting (IPTW) with propensity scores. The actuarial five-year biochemical failure-free survival rates were 92.9% and 96.7% (p = 0.1847; p = 0.077 in IPTW) for HDR-BT and IG-IMRT, respectively; they were 100% and 95.8% (p = 0.286) for the low-risk group, 95.6% and 92% (p = 0.42) for the intermediate-risk group, 90.4% and 84.9% (p = 0.1059; p = 0.04 in IPTW) for the high-risk group, and 87.1% and 89.2% (p = 0.3816) for the very-high-risk group. In the assessment of accumulated incidences of grade ≥ 2 toxicity (Common Terminology Criteria for Adverse Events version 4.0) at five years, HDR-BT monotherapy showed higher genitourinary toxicity (11.9%) than IG-IMRT (3.3%) (p < 0.0001). The gastrointestinal toxicity was equivalent for HDR-BT (2.3%) and IG-IMRT (5.5%) (p = 0.063). No Grade 4 or 5 toxicity was detected in either modality. HDR-BT showed higher genitourinary toxicity than IG-IMRT. HDR-BT and IG-IMRT showed equivalent outcomes in low-, intermediate-, and very-high-risk groups. For high-risk patients, HDR-BT showed potential to improve prostate-specific antigen (PSA) control rate compared to IG-IMRT. MDPI 2018-09-10 /pmc/articles/PMC6162691/ /pubmed/30201941 http://dx.doi.org/10.3390/cancers10090322 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamazaki, Hideya Masui, Koji Suzuki, Gen Nakamura, Satoaki Shimizu, Daisuke Nishikawa, Tatsuyuki Okabe, Haruumi Yoshida, Ken Kotsuma, Tadayuki Tanaka, Eiichi Otani, Keisuke Yoshioka, Yasuo Ogawa, Kazuhiko High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title_full | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title_fullStr | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title_full_unstemmed | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title_short | High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer |
title_sort | high-dose-rate brachytherapy monotherapy versus image-guided intensity-modulated radiotherapy with helical tomotherapy for patients with localized prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162691/ https://www.ncbi.nlm.nih.gov/pubmed/30201941 http://dx.doi.org/10.3390/cancers10090322 |
work_keys_str_mv | AT yamazakihideya highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT masuikoji highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT suzukigen highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT nakamurasatoaki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT shimizudaisuke highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT nishikawatatsuyuki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT okabeharuumi highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT yoshidaken highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT kotsumatadayuki highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT tanakaeiichi highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT otanikeisuke highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT yoshiokayasuo highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer AT ogawakazuhiko highdoseratebrachytherapymonotherapyversusimageguidedintensitymodulatedradiotherapywithhelicaltomotherapyforpatientswithlocalizedprostatecancer |